Evaluation of topotecan in resistant and relapsing multiple myeloma: A southwest oncology group study

Eric H. Kraut*, John J. Crowley, James L. Wade, Leslie R. Laufman, Melissa Alsina, Sarah A. Taylor, Sydney E. Salmon

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

43 Scopus citations

Abstract

Purpose: Topotecan is a topoisomerase I inhibitor with antitumor activity against hematologic and solid tumor malignancies. We evaluated its activity in refractory and relapsing multiple myeloma patients who had received one prior chemotherapeutic regimen. Patients and Methods: Toptecan 1.25 mg/m2/d was administered aS a 30-minute infusion far 5 days repeated every 3 weeks. Granulocyte colony-stimulating factor (G-CSF) 5 μg/kg/d subcutaneously was administered after the first course of treatment if neutropenia was dose-limiting. Results: Forty-six patients entered the study, with 43 patients eligible. The major toxicity was granulocytopenia with grade 3 or better occurring in 40 of 43 patients treated; 21 of 43 patients developed grade 3 or greater thrombocytopenia. Other significant toxicity included mild nausea in 23 patients and mild vomiting in 13 patients. The overall response rate (partial response or better) was 16% (95% confidence interval, 7% to 31%), with responses occurring in both relapsed and refractory patients. Responses have lasted 70 to 477+ days, with a median progression-free survival duration of 13 months and median survival time of 28 months. Conclusion: Topotecan has activity in refractory and relapsing multiple myeloma. Future investigation of topotecan in multiple myeloma including combination therapy and the study of other topoismerase I inhibitors is warranted.

Original languageEnglish (US)
Pages (from-to)589-592
Number of pages4
JournalJournal of Clinical Oncology
Volume16
Issue number2
DOIs
StatePublished - Jan 1 1998

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Evaluation of topotecan in resistant and relapsing multiple myeloma: A southwest oncology group study'. Together they form a unique fingerprint.

Cite this